Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (February 2022)
9 slides from Medical Developments International's investor presentation, Feb 24, 2022
Slide 1: MVP FY22 Half Year Results & Investor Presentation
MVP FY22 Half Year Results & Investor Presentation Gordon Naylor – Chair Brent MacGregor - CEO 25 February 2022 10am AEDT Investors can register in advance for this presentation via the following link: https://us02web.zoom.us/meetin g/register/tZMpceqpqTsvH9WuY m0evrIBU3ydUplXsxhN 1
Slide 2: Disclaimer
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Half Year Highlights
Half Year Highlights FY22 H1 Statutory Financials $m Renewed focus delivering across key Gross Revenue 9.9 markets Gross Margin 5.6 ▪ Strong rebound for Penthrox in Australia continuing on EBIT (9.4) momentum from H2 FY21 Net Profit/(Loss) After Tax (7.4) ▪ Penthrox EU – first full 6 months under MV
Slide 4: Gross Revenue Bridge
Gross Revenue Bridge Gross sales revenue grew 55% ▪ Non-recurring contract income in FY21 H1 ▪ Following handback from previous distributor, Australian Penthrox sales have returned to pre- pandemic levels despite restrictions in NSW and VIC ▪ EU Penthrox sales have been robust despite restricted hos
Slide 5: EBIT Bridge
EBIT Bridge EBIT comparable when excluding non-operating impacts ▪ FY21 H1 contract income is non-recurring ▪ JobKeeper subsidies ended in March 21 ▪ Human capital represents investment in personnel and share based payments ▪ Impairments relate to the FY22 H1 Veterinary goodwill write off and CSIRO
Slide 6: Update on FY22 plans
Update on FY22 plans FY22 Planned Enhancements Progress Update ▪ Further changes in AU; augmentation of ▪ Largely complete despite Germany and Italy Europe team, based on Germany and Italy deferrals outcomes ▪ Further expansion of Medical Affairs ▪ Complete resources in Europe and at global HQ ▪ Ove
Slide 7: "Selfie" Investment Formally Approved
“Selfie” Investment Formally Approved • Toward Commercialisation • Capital Investment • Regulatory and Commercial Development • Improved usability and patient safety – pouring eliminated • All-in-one device • Pre-loaded 3ml dose • Integrated Activated Carbon (AC) Chamber • Equivalent performance and
Slide 8: We have focused our efforts on our growth assets
We have focused our efforts on our growth assets • The veterinary segment will be wound down • We will exit a range of non-core medical equipment products • We have terminated our Active Pharmaceutical Ingredient (API) Flow manufacturing agreement with CSIRO to focus our resources on our Penthrox le
Slide 9: We are Headed in the Right Direction
We are Headed in the Right Direction • We are encouraged by the growth we have seen in our key markets • France (Penthrox) • Australia (Penthrox and Respiratory) • US (Respiratory) • Our underlying business is gaining strength • Our key projects to support long-term growth are moving forward • We ar
Medical Developments International — Investor Presentation (February 2022) on 6ix